Case Report

Rare coexistence of mediastinal hepatoid adenocarcinoma, idiopathic azoospermia and horseshoe kidney: a case report and review of the literature

Chun-Hong Hu¹, Qiu-Li Li², Hai-Peng Li², Song-Qing Fan³, Hai-Xia Zhang⁴, Xian-Ling Liu¹, Yan He¹, Ming Huang¹, Min Lu¹, Si-Si Wang¹, Fang Wu¹

Departments of ¹Oncology, ³Pathology, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha 410011, China; ²Department of Neurology, The First People’s Hospital of Chenzhou, University of South China, 102 Luojiaying Road, Chenzhou 423000, China

Received June 25, 2015; Accepted July 29, 2015; Epub September 1, 2015; Published September 15, 2015

Abstract: Hepatoid adenocarcinoma (HAC) is the term proposed for a special type of extrahepatic tumors, which is similar to the hepatocellular carcinoma (HCC) both in the histopathology and immunohistochemistry. HAC has been observed in the stomach, colon, pancreas, gall bladder, lung and female genital tract, but rarely in the mediastinum. Now we describe a case of a 28-year-old Chinese male with primary mediastinal HAC with lung and liver metastasis. In this patient, HAC was associated with horseshoe kidney and idiopathic nonobstructive azoospermia. It seemed derivation abnormalities during organogenesis in the embryo stage played a significant role in the pathogenesis of HAC, horseshoe kidney and idiopathic nonobstructive azoospermia. Even the pathogenesis was still unknown; it may merit consideration of HAC together with horseshoe kidney and idiopathic nonobstructive azoospermia as a syndrome rather than as a spectrum of coincidental diseases. Furthermore, we found the HAC is a neoplasm with unfavorable outcomes despite aggressive and multi-protocol strategies. The serum alpha fetoprotein (AFP) should be regarded as a useful marker for diagnostic purposes and therapeutic response evaluation of HAC.

Keywords: Hepatoid adenocarcinoma, hepatocellular carcinoma, horseshoe kidney, idiopathic nonobstructive azoospermia, alpha fetoprotein, chemotherapy

Introduction

Hepatoid adenocarcinoma (HAC) is the term proposed for a rare type of extrahepatic aggressive tumor, which shows histological resemblance to hepatocellular carcinoma (HCC) [1, 2]. The tumor cells differentiate into liver cells due to certain abnormalities in differentiation during embryonic development [3, 4]. The origin and biology of these tumors is unclear. Only one case of HAC in the thymus has been reported, which had no elevated level of serum AFP [4]. In this case, the patient present a rare AFP-producing mediastinal HAC. Meanwhile, we report the coexistence of HAC, horseshoe kidney and idiopathic nonobstructive azoospermia, and raise the hypothesis that these may be a syndrome rather than a serious of coincidental diseases.

This study was approved by the ethics committee of the Second Xiangya Hospital of Central South University (Changsha, China). Patient provided written informed consent.

Case presentation

A 28-year-old Chinese male was admitted to The Second Xiangya Hospital of Central South University (Changsha, China) due to chest and shoulder pain on May 2013. He has no Jaundice, spider angiomas, abdominal pain and distension. The patient’s medical history was remarkable, including idiopathic nonobstructive azoospermia and horseshoe kidney. He had no smoking or drinking habits. He had no hepatitis and tuberculosis. Liver and spleen were impalpable. Markers for hepatitis virus were all negative. Results of laboratory workup revealed
aspartate aminotransferase and alanine aminotransferase level were within the normal range. Endocrinological data showed that Follicle stimulating hormone (FSH) was 25.350 U/L↑, Luteinizing hormone (LH) was 9.420 U/L↑, Testosterone (T) was normal. Serum-human chorionic gonadotropin (HCG) was undetectable at <1 mIU/mL. Before the surgery, the level of serum AFP was significantly elevated at 155 278.00 ng/ml. Chromosome karyotyping showed 46XY. Computed tomography (CT) showed single tumor (approx. 18 cm in greatest diameter) in the anterior mediastinum and multiple nodules suspected for metastasis in the liver and bilateral lungs (Figure 1). The first diagnosis seemed to be mediastinal carcinoma with lung and liver metastasis. The mediastinal tumor removal and the left upper lung and the middle lobe of right lung wedge resection were performed. The patient also underwent a US-guided liver biopsy. One month after the operation, the serum AFP level was 7347 ng/ml. Combined with the histological and immunohistochemical findings, the final diagnosis was HAC in the mediastinum with lung and liver metastasis. Adjuvant therapy with CAP (cyclophosphamide/epirubicin/cislatin) was given every 3 weeks for 4 cycles (June 2013-october 2013). The decline of serum AFP level was noticed (from 7347.47 ng/ml to 402 ng/ml). Meanwhile, the CT revealed multiple tumors in the liver and lung were partly remission. On November 2013, a progression of liver and lung metastasis, along with elevated serum AFP level (105 504 ng/mL) was found. He was switched to second-line chemotherapy with gemcitabine and paclitaxel, after two courses of chemotherapy, serum AFP level decreased to 34 686 ng/ml. However, two cycles later, CT scan demonstrated a progression of liver, bilateral pulmonary metastasis and newly developed hilum of lungs metastasis. At the same

Figure 1. Computed tomography scan before surgery in a 28-year old man. A, B: Preoperative CT scan revealing 18 cm in diameter in the anterior mediastinum and horseshoe kidney. C: Chest CT shows multiple tumor in the bilateral lung. D: Abdominal CT reveals multiple nodular, high-density contrast mass in the liver lobe.
Hepatoid adenocarcinoma with high serum AFP in the mediastinum

The serum AFP level reached up to 121,000 ng/mL. He was then put under the third-line chemotherapy (Gemcitabine and Vinorelbine). However, the level of serum AFP rose to 306,081 ng/ml after one course of chemotherapy (Figure 2). The CT findings in liver, hilum of lung show progressive disease. Hepatomegaly was pronounced, with the liver palpable 5-7 cm fingerbreadths below the costal margin. He died on April 1, 2014, eleven months after the diagnosis.

Materials and methods

Sections were stained with hematoxylin and eosin, periodic acid-Schiff. Immunohistochemical staining was performed on the mediastinal and liver tumor cells by the avidin-biotin-peroxidase technique. The panel of primary antibodies revealed in Table 1. Clinical data were obtained from the patients’ record.

Histological findings

Immunohistochemical findings

Immunohistochemistry was performed on mediastinal HACs as well as hepatic metastasis, and both stained positive for hepatocellular markers, such as AFP (Figure 4A), Glypican-3 (Figure 4B). Immunostaining for cytokeratins (CK) and CK18 are helpful in defining HAC. Staining for CK7 is negative. A characteristic marker of about 50% of thymic carcinomas, CD5, was not detected. In additional, mediastinal HACs displayed epithelial membrane antigen (EMA) was focally positive, but negative for β-human chorionic gonadotropin (β-HCG) (Figure 4C), CD30 (Figure 4D), CD15, CD57, LCA, CD20, CD45R0 and CD56. Proliferative activity by Ki67 labeling index was 40%. Both the mediastinal HACs and liver metastasis showed p53 strongly immunoreactivity.

Table 1. Antibodies used in immunohistochemical staining

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Source</th>
<th>Dilution</th>
<th>Mediastinum</th>
<th>Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFP</td>
<td>Dako</td>
<td>1:2000</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Glypican3</td>
<td>Dako</td>
<td>1:100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CK</td>
<td>Dako</td>
<td>1:200</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>CK18</td>
<td>Progen</td>
<td>1:100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>HCG</td>
<td>Dako</td>
<td>1:1000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CEA</td>
<td>Immunotech</td>
<td>1:5000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>EMA</td>
<td>Dako</td>
<td>1:100</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CD30</td>
<td>Dako</td>
<td>1:200</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CD55</td>
<td>Biocare</td>
<td>1:50</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LCA</td>
<td>Dako</td>
<td>1:500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CD20</td>
<td>Dako</td>
<td>1:500</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CD45R0</td>
<td>Dako</td>
<td>1:400</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CD56</td>
<td>Novocastra</td>
<td>1:50</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>S100</td>
<td>Dako</td>
<td>1:100</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TTF-1</td>
<td>Cell Marque</td>
<td>1:200</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CK7</td>
<td>Progen</td>
<td>1:100</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vimentin</td>
<td>Dako</td>
<td>1:100</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CEA</td>
<td>Dako</td>
<td>1:2300</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CD5</td>
<td>Novocastra</td>
<td>1:100</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Hepatoid adenocarcinoma with high serum AFP in the mediastinum

Discussion

We describe an extremely unique HAC in the mediastinum with a markedly elevated serum AFP. Generally, HAC was described in the stomach, colon, gallbladder, extrahepatic duct, gall bladder, lung and ovary [3, 5-11]. Only one case of HAC in the thymus has been reported, which had no elevated level of serum AFP [4]. Since serum AFP has long been used for the screening and diagnosis of HCC, HCC with mediastinal metastasis was highly suspected at this patient. However, primary HCC often appears as a single tumor, and usually accompanied with underlying risk factors, such as liver cirrhosis, chronic hepatitis B or chronic hepatitis C infection. The preoperative examination revealed the patient was negative for chronic hepatitis B and C. Microscopically, polygonal tumor cells proliferating in both trabecular and intestinal-like structures in HE staining indicates HAC [4, 11]. Furthermore, all HAC tumors were positive for both CK18 and glypican 3 (GPC-3) staining (100%) [11]. Therefore, the final diagnosis of HAC in the mediastinum with liver and lung metastasis was established.

The patient had a remarkable history including horseshoe kidney and idiopathic nonobstructive azoospermia. A horseshoe kidney is the most common congenital renal fusion anomaly. It usually occurs with other congenital anomalies. Approximately 29% of azoospermic men have underlying genetic abnormalities, commonly including chromosomal or gene defects and epigenetic alteration [12]. An epidemiological research showed there was a high incidence of cancer in azoospermic men [13]. The hypothesis revealed that impairment of the process of meiosis and mitosis occurred during fetal life would affect spermatogenesis and increase the possibility of carcinogenesis. Many literatures also manifested the occurrence of HAC resulted from certain abnormalities in endodermal derivation [3, 4]. Meanwhile, genital apparatus and urinary system are both mesoderm-derived [14]. It seemed that derivation abnormalities during organogenesis would be the cause for this unique association. The patient may have a underlying genetic basis that occurred during the fetal life, and the association may be a constellation of diseases with the same syndrome rather than a coincidence.

Up to now, HAC is characterized by aggressive clinical course and poor prognosis because of its extensive hematogenous metastasis to the liver and early metastasis to regional lymph nodes [15-17]. One-year survival was 55% and median overall survival 11 months [17]. As lacking of data and convincing-hypothesis of about the origin and biology of these tumors and no standard treatment exists. Based on its location, it was reported that adjuvant therapies consisting of Paclitaxel and Carboplatin in gynecological tumors, mostly 5-fluorouracil (5-FU), Cisplatin, and Irinotecan in gastrointestinal HAC were performed [17]. Since chemo-

Figure 3. Hematoxylin-eosin and microscopic image of mediastinal mass (A) and liver metastasis (B). (A) Medium-sized, cuboidal and polygonal tumor cells with prominent nucleoli, with pseudoglandular formation. (B) The hepatic tumor were poorly differentiated and focally showed glandular structure arrangement and with hepatoid differentiation.
therapy for HAC in mediastinum has not been reported, cyclophosphamide, Epirubicin, Cisplatin (CAP) was administered based on its location. The patient had temporary improvement but relapsed shortly after multi-protocol chemotherapy (Gemcitabine, paclitaxel and Vinorelbine). He died 11 months after the diagnosis. Considering of sharing behavior with the primary liver tumor cells, in a recently reported case of HAC originating in the peritoneal cavity, Metzgeroth et al. administered Sorafenib, given at a daily dose of 400 mg. Despite temporary clinical improvement, the patient died 6 months after the diagnosis [17]. Whether to treat it as a cancer of the mediastinal tumor or rather a cancer of the liver from the onset, clinical benefit is poor. In conclusion, HAC is a another entity with a poor prognosis despite an aggressive and multi-protocol strategy. Since the poor diagnosis of HAC, it is extremely important to make an earlier diagnosis to evaluate treatment method. Furthermore, the serum AFP should be regarded as a vital marker for diagnostic purposes and therapeutic response evaluation of HAC.

In summary, HAC is a new group of tumor with unfavorable prognosis, showing the similarity of histological appearance of HCC and often occurring in the stomach. This report describes the first case of mediastinal HAC with markedly elevated level of serum AFP. We also describe an extremely rare case of HAC in the mediastinum, with horseshoe kidney and idiopathic nonobstructive azoospermia. In terms of the poor prognosis of HAC, further studies about pathogenesis and medical genetics are needed to improve the clinical benefit.

Disclosure of conflict of interest

None.
Hepatoid adenocarcinoma with high serum AFP in the mediastinum

Address correspondence to: Dr. Fang Wu, Department of Oncology, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha 410011, China. Tel: 0086-13574858332; Fax: 0086-731-85295929; E-mail: doctor_wufang@126.com

References


